Posted by SLS on December 30, 2013, at 16:53:03
In reply to Re: Cariprazine - A better Abilify?, posted by phidippus on December 30, 2013, at 14:02:40
> What impliccations does the D3 action have?
>
> EricThe actions of cariprazine comprise more limibic (D3) and less striatal (D2) involvement than Abilify as a DA receptor partial agonist. My unprofessional conclusion is that this would produce less risk of motoric EPS (akathisia might remain problematic) and greater therapeutic effects on depressive mood and negative shizoid symptomatology (deficit syndrome). Even if my thinking is flawed, in the absence of safety issues, I would want to try cariprazine anyway, as it might work better for depression and produce less weight gain than Abilify.
The FDA is not impressed with cariprazine because they do not find any advantage to this drug over those currently available (Efficacy and side effects). This is dangerous thinking, in my estimation. It will prevent a subset of people from having access to a drug that might save their lives or enhance their quality. The FDA can't yet conclude using the available science that cariprazine won't help people who were not helped by currently available drugs. Why have more than one SSRI? Hopefully, the FDA is asking only for evidence that will better define the dosage range for cariprazine. I don't think they have any problems with the data demonstrating efficacy.
- Scott
Some see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1052699
URL: http://www.dr-bob.org/babble/20131209/msgs/1057241.html